Opexa Therapeutics And Myelin Repair Foundation Partner On Novel Multiple Sclerosis Research Program September 8, 2008
Opexa Therapeutics, Inc. (NASDAQ:OPXA), a company dedicated to the development of patient-specific cellular therapies for the treatment of autoimmune diseases such as multiple sclerosis (MS) and diabetes, announced the establishment of a novel MS research partnership with the Myelin Repair Foundation, Inc. (MRF).

add to del.icio.us
Print This Post































Leave a Reply